NCI-H1975 Cells

The NCI-H1975 cell line is a well-established model derived from human non-small cell lung carcinoma (NSCLC), specifically adenocarcinoma. This cell line is particularly significant due to its dual mutations in the epidermal growth factor receptor (EGFR) gene. It harbors the L858R activating mutation in exon 21 and the T790M mutation in exon 20, which confers resistance to first-generation tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib. These genetic characteristics make NCI-H1975 a valuable tool for studying drug resistance mechanisms and testing next-generation EGFR inhibitors. The T790M mutation alters the ATP-binding pocket of EGFR, reducing the efficacy of earlier EGFR inhibitors while maintaining receptor signaling activity. This property has driven research into third-generation inhibitors, such as osimertinib, which selectively target T790M mutant EGFR while sparing wild-type EGFR, reducing off-target effects. Studies using NCI-H1975 have contributed to understanding the structural and functional impacts of these mutations on EGFR-mediated signaling pathways, including downstream effects on PI3K/AKT and RAS/RAF/MEK/ERK pathways, which are pivotal in tumor cell proliferation and survival. In addition to its role in drug resistance research, NCI-H1975 is employed in preclinical evaluations of combination therapies that aim to overcome resistance by targeting multiple pathways. Its well-characterized genetic and molecular profile, including detailed data on copy number variations and mutational landscapes, has solidified its status as an essential model in the study of NSCLC biology and therapeutic development.